PMID- 31602329
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220410
IS  - 2078-6891 (Print)
IS  - 2219-679X (Electronic)
IS  - 2078-6891 (Linking)
VI  - 10
IP  - 5
DP  - 2019 Oct
TI  - First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic 
      patients: a good choice beyond age.
PG  - 910-917
LID - 10.21037/jgo.2019.06.02 [doi]
AB  - BACKGROUND: Nab-paclitaxel plus gemcitabine represents one of the standard 
      regimens for first line treatment of metastatic pancreatic cancer (mPC). Few data 
      are available on nab-paclitaxel plus gemcitabine in geriatric population. Our 
      study aims to show whether this schedule can be feasible in the elderly as 
      first-line treatment for mPC. METHODS: We retrospectively analyzed the data of 64 
      mPC patients (>/=65 years old) treated according to the MPACT schedule. RESULTS: 
      Median age was 69.5 years (range, 65-80 years); after a median of 5 cycles 
      administered (range, 1-12), the most common adverse events (AEs) were grade 2 
      alopecia (46.9%), anemia (17.2%) and hypertransaminasemia (10.9%); all grades 
      neutropenia occurred in 20.3% of pts. Global incidence of grade 3 and 4 
      toxicities were 26.5% and 0%, respectively, and no patients stopped treatment due 
      to unacceptable toxicity. Stable disease (SD) was observed in 31.2% of patients, 
      with a disease control rate (DCR) and overall response rate of 57.8% and 26.6%, 
      respectively. After a median follow-up of 18 months, median progression free 
      survival (PFS) was 8 months (95% CI: 6.3-9.6) and median OS was 12.0 months (95% 
      CI: 8.4-15.6). The univariate analysis for overall survival (OS) showed that only 
      ECOG performance status was an independent prognostic factor for survival. 
      CONCLUSIONS: Nab-paclitaxel plus gemcitabine schedule is feasible and effective 
      in the "daily clinical practice" geriatric population.
CI  - 2019 Journal of Gastrointestinal Oncology. All rights reserved.
FAU - Petrillo, Angelica
AU  - Petrillo A
AD  - Division of Medical Oncology, Department of Precision Medicine, University of 
      study of Campania "L. Vanvitelli", Napoli, Italy.
FAU - Pappalardo, Annalisa
AU  - Pappalardo A
AD  - Division of Medical Oncology, Department of Precision Medicine, University of 
      study of Campania "L. Vanvitelli", Napoli, Italy.
FAU - Calabrese, Filomena
AU  - Calabrese F
AD  - Division of Medical Oncology, AORN, "A Cardarelli", Napoli, Italy.
FAU - Tirino, Giuseppe
AU  - Tirino G
AD  - Division of Medical Oncology, Department of Precision Medicine, University of 
      study of Campania "L. Vanvitelli", Napoli, Italy.
FAU - Pompella, Luca
AU  - Pompella L
AD  - Division of Medical Oncology, Department of Precision Medicine, University of 
      study of Campania "L. Vanvitelli", Napoli, Italy.
FAU - Ventriglia, Jole
AU  - Ventriglia J
AD  - Division of Medical Oncology, Department of Precision Medicine, University of 
      study of Campania "L. Vanvitelli", Napoli, Italy.
FAU - Laterza, Maria Maddalena
AU  - Laterza MM
AD  - Division of Medical Oncology, Department of Precision Medicine, University of 
      study of Campania "L. Vanvitelli", Napoli, Italy.
FAU - Caterino, Marianna
AU  - Caterino M
AD  - Division of Medical Oncology, Department of Precision Medicine, University of 
      study of Campania "L. Vanvitelli", Napoli, Italy.
FAU - Sforza, Vincenzo
AU  - Sforza V
AD  - Medical Oncology Department, Consorcio Hospital General Universitario de 
      Valencia, Valencia, Spain.
FAU - Iranzo, Vega
AU  - Iranzo V
AD  - Medical Oncology Department, Consorcio Hospital General Universitario de 
      Valencia, Valencia, Spain.
FAU - Biglietto, Maria
AU  - Biglietto M
AD  - Division of Medical Oncology, AORN, "A Cardarelli", Napoli, Italy.
FAU - Orditura, Michele
AU  - Orditura M
AD  - Division of Medical Oncology, Department of Precision Medicine, University of 
      study of Campania "L. Vanvitelli", Napoli, Italy.
FAU - Ciardiello, Fortunato
AU  - Ciardiello F
AD  - Division of Medical Oncology, Department of Precision Medicine, University of 
      study of Campania "L. Vanvitelli", Napoli, Italy.
FAU - Conzo, Giovanni
AU  - Conzo G
AD  - Department of Cardiothoracic Sciences, University of study of Campania "L. 
      Vanvitelli", Naples, Italy.
FAU - Molino, Carlo
AU  - Molino C
AD  - Division of General Surgery, AORN, "A. Cardarelli", Napoli, Italy.
FAU - De Vita, Ferdinando
AU  - De Vita F
AD  - Division of Medical Oncology, Department of Precision Medicine, University of 
      study of Campania "L. Vanvitelli", Napoli, Italy.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Gastrointest Oncol
JT  - Journal of gastrointestinal oncology
JID - 101557751
PMC - PMC6776800
OTO - NOTNLM
OT  - Pancreatic cancer (PC)
OT  - elderly
OT  - first-line chemotherapy
OT  - metastatic pancreatic adenocarcinoma
OT  - nab-paclitaxel plus gemcitabine
COIS- Conflicts of Interest: A Petrillo: Honoraria from Lilly. V Sforza: honoraria from 
      Celgene for "proyecto enlace" and during that period he collected these data. F 
      Ciardiello: Advisory Boards: Roche, Amgen, Merck, Pfizer, Sanofi, Bayer, Servier, 
      BMS, Celgene, Lilly; Institutional Research Grants: Bayer, Roche, Merck, Amgen, 
      AstraZeneca, Takeda. M Orditura: Honoraria from Italfarmaco, EISAI, epionpharma, 
      Roche. F De Vita: Advisory Boards: Roche, Amgen, Celgene, Lilly. The other 
      authors have no conflicts of interest to declare.
EDAT- 2019/10/12 06:00
MHDA- 2019/10/12 06:01
PMCR- 2019/10/01
CRDT- 2019/10/12 06:00
PHST- 2019/10/12 06:00 [entrez]
PHST- 2019/10/12 06:00 [pubmed]
PHST- 2019/10/12 06:01 [medline]
PHST- 2019/10/01 00:00 [pmc-release]
AID - jgo-10-05-910 [pii]
AID - 10.21037/jgo.2019.06.02 [doi]
PST - ppublish
SO  - J Gastrointest Oncol. 2019 Oct;10(5):910-917. doi: 10.21037/jgo.2019.06.02.